Data-driven modeling and characterization of anti-angiogenic molecule effects on tumoral vascular density

Abstract Angiogenesis is the phenomenon by which new blood vessels are created from preexisting ones. But this natural process is also involved, in a chaotic way, in tumor development. Many molecules have shown particular efficiency in inhibiting this phenomenon, hopefully leading to either: (i) a reorganization of the neovessels allowing a better tumor uptake of cytotoxic molecules (as chemotherapy) or (ii) a deprivation of the tumor vascular network with the view to starve it. However, characterizing the anti-angiogenic effects of a molecule remains difficult, mainly because the proposed physical modeling approaches have barely been confronted to in vivo data, which are not directly available. This paper presents an original approach to characterize and analyze the anti-angiogenic responses in cancerology that allows biologists to account for spatial and dynamical dimensions of the problem. The proposed solution relies on the association of a specific biological in vivo protocol using skinfold chambers, image processing and dynamic system identification. An empirical model structure of the anti-angiogenic effect of a tested molecule is selected according to experimental data. Finally the model is identified and its parameters are used to characterize and compare responses of the tested molecule.

[1]  H. W. Chalkley,et al.  Vascular reactions of normal and malignant tissues in vivo. III. Vascular reactions' of mice to fibroblasts treated in vitro with methylcholanthrene. , 1950, Journal of the National Cancer Institute.

[2]  P. Hahnfeldt,et al.  Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response, and postvascular dormancy. , 1999, Cancer research.

[3]  L. Wein,et al.  Optimal scheduling of radiotherapy and angiogenic inhibitors , 2003, Bulletin of mathematical biology.

[4]  M. Chaplain,et al.  Mathematical Modelling of Angiogenesis , 2000, Journal of Neuro-Oncology.

[5]  Napoleone Ferrara,et al.  VEGF and the quest for tumour angiogenesis factors , 2002, Nature Reviews Cancer.

[6]  Lei Xu,et al.  Normalization of the vasculature for treatment of cancer and other diseases. , 2011, Physiological reviews.

[7]  M. Chaplain,et al.  Continuous and Discrete Mathematical Models of Tumor‐Induced Angiogenesis , 1999 .

[8]  Alberto Gandolfi,et al.  A family of models of angiogenesis and anti-angiogenesis anti-cancer therapy. , 2008, Mathematical medicine and biology : a journal of the IMA.

[9]  Johanna Sápi,et al.  Model-Based Angiogenic Inhibition of Tumor Growth Using Modern Robust Control Method , 2012 .

[10]  Liuping Wang,et al.  Identification of Continuous-time Models from Sampled Data , 2008 .

[11]  Lennart Ljung,et al.  System Identification: Theory for the User , 1987 .

[12]  Levente Kovács,et al.  Flat control of tumor growth with angiogenic inhibition , 2012, 2012 7th IEEE International Symposium on Applied Computational Intelligence and Informatics (SACI).

[13]  P. Young,et al.  Refined Instrumental Variable Identification of Continuous-time Hybrid Box-Jenkins Models , 2008 .

[14]  Urszula Ledzewicz,et al.  Optimal and suboptimal protocols for a class of mathematical models of tumor anti-angiogenesis. , 2008, Journal of theoretical biology.

[15]  Jeffrey W. Clark,et al.  Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  A. Ullrich,et al.  Inhibition of tumor growth, angiogenesis, and microcirculation by the novel Flk-1 inhibitor SU5416 as assessed by intravital multi-fluorescence videomicroscopy. , 1999, Neoplasia.

[17]  K. Jauch,et al.  Angiogenesis in cancer: molecular mechanisms, clinical impact , 2007, Langenbeck's Archives of Surgery.

[18]  P. Carmeliet,et al.  Molecular mechanisms and clinical applications of angiogenesis , 2011, Nature.

[19]  H. Schättler,et al.  On optimal delivery of combination therapy for tumors. , 2009, Mathematical biosciences.

[20]  Eric Walter,et al.  Identification of Parametric Models: from Experimental Data , 1997 .

[21]  Philip Hahnfeldt,et al.  Simple ODE models of tumor growth and anti-angiogenic or radiation treatment , 2001 .

[22]  H. Schättler,et al.  Tumor Development Under Combination Treatments with Anti-angiogenic Therapies , 2013 .

[23]  Algire Gh Vascular reactions of normal and malignant tissues in vivo. VII. Observations on vascular reactions in destruction of tumor homografts. , 1954 .

[24]  H A Lehr,et al.  Scope and perspectives of intravital microscopy--bridge over from in vitro to in vivo. , 1993, Immunology today.

[25]  Levente Kovács,et al.  Model-based analysis and synthesis of tumor growth under angiogenic inhibition: A case study , 2011 .

[26]  L. Kovács,et al.  Model-based optimal therapy for high-impact diseases , 2013, 2013 IEEE 17th International Conference on Intelligent Engineering Systems (INES).

[27]  Sophocles J. Orfanidis,et al.  Introduction to signal processing , 1995 .

[28]  Levente Kovács,et al.  Model-based angiogenic inhibition of tumor growth using feedback linearization , 2013, 52nd IEEE Conference on Decision and Control.

[29]  Levente Kovács,et al.  Model-based angiogenic inhibition of tumor growth using modern robust control method , 2014, Comput. Methods Programs Biomed..

[30]  Malcolm W R Reed,et al.  A critical analysis of current in vitro and in vivo angiogenesis assays , 2009, International journal of experimental pathology.

[31]  R. Muschel,et al.  Dual inhibition of the PI3K/mTOR pathway increases tumor radiosensitivity by normalizing tumor vasculature. , 2012, Cancer research.

[32]  K. Hoang-Xuan,et al.  Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. , 2014, The New England journal of medicine.

[33]  T. Bastogne,et al.  Tumor vascular responses to antivascular and antiangiogenic strategies: looking for suitable models. , 2012, Trends in biotechnology.